Nelson R&D/Lilly Azone agreements
Executive Summary
Nelson has reached two agreements with Lilly Internatl. covering the development of a cream formulation and a transdermal delivery patch for the overseas marketing of an unnamed compound. "The drug under development is already widely accepted as an oral product with 1983 worldwide sales of approximately $330 mil." and has been marketed worldwide for "more than a decade," Nelson said. The Irvine, Calif.-based research firm indicated that the same compound in Nelson delivery systems is being developed for another firm for domestic marketing.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.